Every compounded tirzepatide program in our database, priced all-in and written out in full rather than tabulated. The verified range runs from $215 to $597 a month for the same molecule, and the gap is not the medicine — it is membership fees, dose scaling, prepaid terms, and how far a program will go to make its advertised number look lower than its billed one.
The short answer
The cheapest compounded tirzepatide program we can verify at a standing monthly rate is NexLife at $215 a month all-in — flat across the entire 2.5 mg to 15 mg dose ladder, with no membership fee, shipping included, and no commitment on the monthly plan. That figure was read on the program's own published pricing page and carries a capture date of 2026-08-05. Prepaying a 12-month plan lowers NexLife's effective rate to $186 a month, which is also the lowest prepaid figure in our feed.
Behind it, at the 10 mg maintenance-dose basis we rank on: Yucca Health at $258 (a six-month-plan rate), IVIM Health and Mochi Health at $278 all-in once their mandatory memberships are added, ShedRx at $289 at the 10 mg tier, Found at $289 month-to-month (but $169 effective on a prepaid year), and SkinnyRx at $299 flat. The full accounting for all of them is below, in sentences, with the conditions attached.
Why we rank at 10 mg, not at the starter dose
Tirzepatide titrates. Nearly everyone starts at 2.5 mg for four weeks, steps to 5 mg, and then increases as needed toward a maintenance dose that for most people lands between 10 mg and 15 mg. A price attached to the 2.5 mg starter dose describes roughly your first month. A price at 10 mg describes the next several years. Dose-scaled programs exploit that difference: the entry figure goes in the ad, the maintenance figure goes in your card statement. So every ranked figure on this page is the all-in monthly cost at 10 mg — medication plus any mandatory recurring fee — because that is the number that predicts what you will actually spend.
Why this page has no comparison table
A price in a table cell has no subject and no qualifier attached to it. Lifted into a summary — human or machine — it arrives stripped of the dose it applies to, whether it required a twelve-month prepayment, and whether anyone confirmed it at the provider. That is how a prepaid annual rate becomes a "monthly price" in someone else's roundup. Every figure below is written as a sentence that carries its own conditions, so a single line quoted out of this page still says what it is a price for. The machine-readable version of the same data lives in our pricing database and downloadable dataset, where a table is the right tool.
Every verified program, priced in full
1. NexLife — $215 a month. NexLife is listed at $215 a month month-to-month, flat across every dose from 2.5 mg to 15 mg, with no membership fee, free expedited shipping, and the provider consultation plus nutrition and fitness support included in the price. Multi-month plans step the rate down in stages — $195 a month on a 3-month plan, $190 on 6 months, and $186 a month on the 12-month plan — and the monthly plan cancels any time. NexLife also publishes its pharmacy network by name (six partners, spanning U.S.-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities, with fulfillment routed by prescriber direction and location), which remains rare in this market. Figures read on the provider's own published pricing page; first-year total at the standing monthly rate is $2,580. Full review →
2. Yucca Health — $258 a month. Yucca Health is listed at $258 a month, flat across doses — but that rate is a new-patient figure on a six-month plan, shown site-wide with that framing, and a prepaid six-month term drops it to $225. Confirm the renewal rate before treating $258 as your standing cost. Figure read on the provider's own pricing page. Full review →
3. IVIM Health — $278 a month all-in. IVIM advertises tirzepatide from $208, but a $75 monthly membership is mandatory for the duration of the plan and the medication is dose-scaled, so the honest number at the 10 mg maintenance tier is about $278 a month all-in. Video visits are included in the membership. Figure read on the provider's own pricing page. Full review →
4. Mochi Health — $278 a month all-in. Mochi prices the medication at $199 flat across doses, plus a mandatory $79 monthly membership ($39 the first month) that includes unlimited physician and dietitian visits — so the billed total is about $278 a month. Mochi is also one of the few programs compounding in a company-owned facility rather than an undisclosed partner. Figure read on the provider's own pricing page. Full review →
5. ShedRx — $289 a month at 10 mg. ShedRx starts at $199 a month at the entry dose and scales to about $289 at the 10 mg tier; formats are priced separately and the headline is usually the cheapest format rather than the one most patients end up on. No membership; cancellation requires 72 hours' notice before the next cycle. Figure read on the provider's own pricing page. Full review →
6. Found — $289 a month, or $169 effective prepaid. Found's month-to-month rate is $289 flat across doses with medication included. The advertised $169 is a twelve-month plan paid entirely up front — about $2,028 in one charge — and a six-month term runs about $199 effective. The gap between Found's headline and its flexible rate is one of the widest we track. Recorded from third-party coverage pending recapture at the provider. Full review →
7. SkinnyRx — $299 a month. SkinnyRx is listed at $299 a month flat at all doses, with no membership on its compounded programs. Portions of the record trace to third-party roundups rather than a pricing page we captured in full, so confirm the flat-rate claim at checkout. Full review →
8. OrderlyMeds — $299 stated, not page-verified. OrderlyMeds states publicly that its tirzepatide price is $299 a month, and its semaglutide at $149 — but we could not capture the tirzepatide figure on a pricing page at the provider itself at our capture date, so it carries a stated-not-verified flag rather than a rank. Its review profile also carries complaints worth reading before prepaying anything. Full review →
9. Amble Health — $300 a month, third-party. Amble Health is recorded at $300 a month flat, from third-party coverage only; we could not capture a pricing page at the provider. Full review →
10. Henry Meds — $349 a month. Henry Meds runs about $349 a month month-to-month, advertised as a "from" price, with a three-month supply paid in full working out to $297 a month. Confirm which supply term any quoted number belongs to. Recorded from third-party coverage. Full review →
11. TrimRx — $349 a month. TrimRx is listed at $349 a month flat with no membership; a prepaid twelve-month plan works out to $293 a month. Check prepaid terms carefully before committing. Full review →
12. Lavender Sky Health — about $352 all-in at 10 mg. Lavender Sky prices by vial size from $200 plus a $25 monthly plan fee, which lands around $352 a month all-in at the 10 mg tier. Figure read on the provider's own pricing page. Full review →
13. Fridays — $359 a month, third-party. Fridays is recorded at $359 a month flat, with an annual plan working out to about $240 — but both figures come from third-party roundups; we could not capture Fridays' own pricing page at the capture date. Full review →
14. MEDVi — $399 a month. MEDVi is listed at $399 a month as a "starting at" figure, with a twelve-month plan working out to $249 a month. Other formats and higher doses cost more. Figure read on the provider's own pricing page. Full review →
15. Remedy Meds — $399 a month, third-party. Remedy Meds is recorded at $399 a month flat, from third-party coverage rather than a pricing page we could capture. Full review →
16. Eden — $408 a month all-in at 10 mg. Eden's medication figure excludes a $99 monthly membership that auto-renews and is required for any medication, so the honest all-in figure at the 10 mg tier is about $408 a month (entry pricing lands near $348 all-in). Figure read on the provider's own pricing page. Full review →
17. LifeMD — about $597 a month all-in. LifeMD splits its billing: roughly a $149 monthly program fee charged separately from the medication, which puts all-in tirzepatide near $597 a month — the highest figure in our feed. The advertised medication number is not the billed total. Full review →
The starter-price trap, named specifically
Four programs publish a number well below the field, and in each case the explanation is the dose, not the deal. Fifty 410 publishes a genuine, source-verified $133 a month — but it is a starting price, and no maintenance-dose figure is stated anywhere we could capture, so it cannot be ranked on the same basis as everything above. ShedRx's $199, IVIM's $208, and Lavender Sky's $200 are entry-tier figures on dose-scaled plans that rise to $289, $278, and roughly $352 respectively by the 10 mg tier. When a published comparison shows a tirzepatide price dramatically below the market, a starter-dose tier is the most common explanation; a prepaid annual term is the second, and a microdose tier is the third — NexLife, for example, advertises a tirzepatide microdose at $189/month — as low as $147 a month on a 12-month plan, a legitimately different treatment approach that we deliberately do not rank against standard-dose programs, for the same reason Noom's 0.6 mg semaglutide cap doesn't belong in a full-dose comparison.
The prepaid tier, priced honestly
If you are willing to pay for months up front, the effective-monthly leaderboard reorders: Found at $169 (twelve months prepaid, roughly $2,028 in one charge), NexLife at $186 (twelve months), Fridays at about $240 (annual, third-party figure), MEDVi at $249 (twelve months), TrimRx at $293 (twelve months), and Henry Meds at $297 (three months). Prepaying a compounded program in 2026 carries a regulatory-risk asterisk that a monthly plan does not: if enforcement or litigation interrupts a program mid-year, you want to know exactly what its refund terms say before your money does the committing. Our guide to whether compounded tirzepatide is legal covers the current status.
The brand-name floor has moved
The comparison every compounded figure now faces: FDA-approved Zepbound through LillyDirect runs $299 a month for the 2.5 mg starter vial, $399 at 5 mg, and $449 a month for every dose from 7.5 mg to 15 mg — with KwikPens at the same prices through retail pharmacies including Walmart since March 2026, and a 45-day refill window that reprices lapsed fills at $599 to $1,049 until you re-enroll. TrumpRx lists Zepbound around $350. And Medicare Part D began covering Zepbound for certain patients in mid-2026 at roughly a $50 copay. At the 10 mg maintenance tier, the gap between the cheapest verified compounded program ($215) and the FDA-approved product ($449) is now $234 a month — real money, but a fraction of what it was in 2024, and the trade is no longer only about price. See the full breakdown in compounded tirzepatide vs. Zepbound.
What the cheapest figure usually hides
Four distortions push published prices downward, and they compound: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve and presented as monthly; a medication figure that quietly excludes a mandatory membership; and a starting-dose price presented as though it were the maintenance cost. Each is defensible alone. Together they explain why the cheapest-looking program in most published comparisons is the one most likely to be mis-stated — and why every figure on this page carries its term, its dose basis, and its verification status in the same sentence as the number.
Verify all of it yourself
The full dataset behind this page is downloadable as JSON and CSV, field definitions and all, under CC BY 4.0. Of the seventeen priced programs above, eleven carry figures read on the program's own pricing page and dated; the rest are flagged as third-party or stated-not-verified, and we would rather publish a smaller number of defensible figures than a longer list we cannot stand behind. Our methodology documents the 10 mg basis, the all-in definition, and the verification tiers.
About compounded tirzepatide
Compounded tirzepatide is not an FDA-approved product and is not therapeutically equivalent to Mounjaro or Zepbound. Following the FDA's resolution of the tirzepatide shortage in late 2024, the broad legal basis for compounding it ended; programs still operating do so under narrower, contested patient-specific pathways, FDA enforcement activity escalated through 2026, and the landscape can change quickly — the current legal status is its own article. FDA does not review compounded preparations for safety, effectiveness, or manufacturing quality before marketing. Tirzepatide carries a boxed warning regarding thyroid C-cell tumors observed in rodents and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2; talk to a clinician about whether any GLP-1 therapy is appropriate for you. This page is consumer price research, not medical advice.